| Literature DB >> 28467808 |
Paula Díez1,2, Nieves Ibarrola2, Rosa M Dégano2, Quentin Lécrevisse1, Arancha Rodriguez-Caballero1, Ignacio Criado1, Wendy G Nieto1, Rafael Góngora1, Marcos González3, Julia Almeida1, Alberto Orfao1, Manuel Fuentes1,2.
Abstract
A wide variety of immunoglobulins (Ig) is produced by the immune system thanks to different mechanisms (V(D)J recombination, somatic hypermutation, and antigen selection). The profiling of Ig sequences (at both DNA and peptide levels) are of great relevance to developing targeted vaccines or treatments for specific diseases or infections. Thus, genomics and proteomics techniques (such as Next-Generation Sequencing (NGS) and mass spectrometry (MS)) have notably increased the knowledge in Ig sequencing and serum Ig peptide profiling in a high-throughput manner. However, the peptide characterization of membrane-bound Ig (e.g., B-cell receptors, BCR) is still a challenge mainly due to the poor recovery of mentioned Ig.Herein, we have evaluated three different sample processing methods for peptide sequencing of BCR belonging to chronic lymphocytic leukemia (CLL) B cells identifying up to 426 different peptide sequences (MS/MS data are available via ProteomeXchange with identifier PXD004466). Moreover, as a consequence of the results here obtained, recommended guidelines have been described for BCR-sequencing of B-CLL samples by MS approaches.For this purpose, an in-house algorithm has been designed and developed to compare the MS/MS results with those obtained by molecular biology in order to integrate both proteomics and genomics results and establish the steps to follow when sequencing membrane-bound Ig by MS/MS.Entities:
Keywords: B-cell receptor; chronic lymphocytic leukemia; immunoglobulin; mass spectrometry; peptide sequencing
Mesh:
Substances:
Year: 2017 PMID: 28467808 PMCID: PMC5522109 DOI: 10.18632/oncotarget.17076
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1General workflow of the study
Patient characteristics
| Sample ID | Agea (yr) | Gender | Diagnosisb % clonal population (from WBC)b V(D)J rearrangementc | MSc Rai stage | Light chainb | Molecular biology sequence | MS/MS processing approachd Gel section digested |
|---|---|---|---|---|---|---|---|
| 1 | 83 | F | CLL 88.1VH4-34(D5-12)J4 | UM-HIII | kappa+dim | Avail. | DTTWhole lane |
| 2 | 58 | F | CLL 21.4VH3-7(D2-15) | M-H0 | kappa+dim | N.A. | DTTWhole lane |
| 3 | 62 | F | CLL 22.1VH4-39(D2-2) | UM-HI | kappa+dim | Avail. | DTTWhole lane |
| 4 | 48 | M | CLL 90.0VH3-30(D2-15)J6 | M-HI | kappa+dim | Avail. | DTTWhole lane |
| 5 | 72 | F | CLL 70.1VH3-7(D2-2) | M-HIII | kappa+dim | N.A. | DTTWhole lane |
| 6 | 49 | M | CLL 80.4VH1-69(D3-10)J6 | M-HIV | kappa+dim | N.A. | Fab preparation kitGel band |
| 7 | 65 | M | CLL 87.5VH1-69(D2-15)J3 | UM-HN.A. | kappa+dim | N.A. | PapainWhole lane |
| 8 | 70 | M | CLL 64.9VH5-a(D5-12) | M-HII-H | kappa+dim | N.A. | PapainGel band |
| 9 | 56 | M | CLL 83.2VH1-69(D2-2)J6 | UM-HII | lambda+dim | N.A. | DTTWhole lane |
Clinical characteristics of the samples used in this study, including the age, gender, diagnosis, V(D)J rearrangement, molecular biology features, and MS/MS processing approach applied to each sample.
a Age at time of sample collection. b From phenotypic studies. c From molecular biology studies. d DTT for denaturation of bead-immobilized immunoglobulins (Ig); papain for isolation of Fab fragments from bead-immobilized Ig; Fab preparation kit for isolation of Fab fragments using a commercial kit.
WBC, white blood cells. MS, mutational status (UM-H, unmutated; M-H, mutated). F, female. M, male. CLL, chronic lymphocytic leukemia. Avail., available. N.A., information not available.
Figure 2Distribution of proteins related to the immune system detected by shotgun MS/MS after processing the samples by three different approaches
(A) Fab preparation kit for isolation of Fab fragments using a commercial kit; (B) papain for isolation of Fab fragments from bead-immobilized immunoglobulins (Ig); (C) DTT for denaturation of bead-immobilized Ig). The MS/MS analysis was performed using Peptide Shaker search engine (neXtProt database, 2016).
Figure 3Peptide length distribution
Graphic showing the number of peptides corresponding to immunoglobulin (Ig) proteins detected by the three approaches (Fab preparation kit for the isolation of Fab fragments using a commercial kit, papain for isolation of Fab fragments from bead-immobilized Ig, and DTT for denaturation of bead-immobilized Ig) using Peptide Shaker as search engine and neXtProt (release February 2016) as database.
Figure 4IGH gene sequences
The framework (FR) and complementary determining regions (CDR) of IGH genes were analyzed and translated into amino acids after DNA-sequencing using the IMGT tool. (A) sample ID 1; (B) sample ID 3; (C) sample ID 4. Violet lines depict the sequence coverage by both DNA-sequencing and MS/MS sequencing using Mascot search engine (UniProt database). Blue lines correspond to sequence coverage by both DNA-sequencing and MS/MS sequencing using Peptide Shaker search engine (neXtProt database). Red lines correspond to predicted tryptic peptides determined by PeptideCutter tool (ExPASy Bioinformatics Resource Portal).
Sequence coverage of IGH genes after DNA-sequencing and MS/MS sequencing and analysis by Mascot and Peptide Shaker search engines
| Sample IDa | Search engineb | Regionc | Region coveraged (%) | Total coveragee (%) |
|---|---|---|---|---|
| Mascot | FR3 | 23/37 (62.1%) | 26/91 (28.6%) | |
| CDR3 | 3/15 (20.0%) | |||
| Peptide Shaker | FR3 | 2/37 (5.4%) | 2/91 (2.2%) | |
| Mascot | FR2 | 6/17 (35.3%) | 17/104 (16.3%) | |
| FR3 | 11/37 (29.7%) | |||
| Peptide Shaker | FR3 | 2/37 (5.4%) | 2/104 (1.9%) | |
| Mascot | FR2 | 6/17 (35.3%) | 9/109 (8.3%) | |
| FR3 | 3/37 (8.1%) | |||
| Peptide Shaker | FR1 | 4/14 (28.6%) | 13/109 (11.9%) | |
| FR3 | 9/37 (24.3%) |
a Sample ID information is available at Table 1. b Mascot search engine was used with UniProt database, whereas Peptide Shaker was tested with the neXtProt database. c It is referred to the framework (FR) or complementary determining region (CDR) of the IGH gene sequence. d Region coverage was calculated considering the number of amino acids in common between DNA-sequencing and MS/MS sequencing in relation to the region (FR or CDR) length. e Total coverage was calculated considering the total number of amino acids in common between DNA-sequencing and MS/MS sequencing of the whole IGH gene in relation to the IGH gene length.
Figure 5Overview of the procedures performed in this study
B cells were purified from CLL peripheral blood using FACSAria. These purified cells were directly employed for BCR-sequencing by molecular biology and also processed to obtain membrane (MB) and cytoplasmic (CYT) proteins. These isolated proteins were used for Fab purification using Pierce Fab preparation kit (A). Moreover, they were Ig-enriched for applying papain protease in solution (B) and denaturation with DTT (C) for the BCR-sequencing by LC-MS/MS.